Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA.
Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, Nakagawa M, Itsui Y, Tasaka M, Sakurai Y, Cheng-Hsin C, Yano M, Ohkoshi S, Aoyagi Y, Maekawa S, Enomoto N, Kohara M, Watanabe M. Sakamoto N, et al. Among authors: yano m. J Gastroenterol Hepatol. 2008 Sep;23(9):1437-47. doi: 10.1111/j.1440-1746.2007.05076.x. Epub 2007 Aug 7. J Gastroenterol Hepatol. 2008. PMID: 17683479 Free PMC article.
Common clinicopathological features of the patients with chronic hepatitis B virus infection who developed hepatocellular carcinoma after seroconversion to anti-HBs--a consideration of the pathogenesis of HBV-induced hepatocellular carcinoma and a strategy to inhibit it.
Tsuboi Y, Ohkoshi S, Yano M, Suzuki K, Tsubata SS, Ishihara K, Ichida T, Sugitani S, Shibazaki K, Aoyagi Y. Tsuboi Y, et al. Among authors: yano m. Hepatogastroenterology. 2006 Jan-Feb;53(67):110-4. Hepatogastroenterology. 2006. PMID: 16506387
[A case with chronic hepatitis C who developed liver cirrhosis due to liver dysfunction caused by pegylated interferon plus ribavirin treatment despite negativity of serum HCV RNA, during therapy].
Ohkoshi S, Morita S, Tanaka Y, Yano M, Takeuchi M, Takahashi H, Ikeda H, Yamagiwa S, Matsuda Y, Nomoto M, Aoyagi Y. Ohkoshi S, et al. Among authors: yano m. Nihon Shokakibyo Gakkai Zasshi. 2011 Feb;108(2):267-74. Nihon Shokakibyo Gakkai Zasshi. 2011. PMID: 21307632 Japanese.
Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B.
Ohkoshi S, Yoshimura A, Yamamoto S, Yano M, Kurita S, Yamazaki K, Aoki YH, Yamagiwa S, Wakabayashi H, Sugiyama M, Takahashi T, Ishikawa T, Matsuda Y, Ichida T, Kamimura T, Aoyagi Y. Ohkoshi S, et al. Among authors: yano m. Hepatol Int. 2008 Sep;2(3):382-7. doi: 10.1007/s12072-008-9084-z. Epub 2008 Jul 25. Hepatol Int. 2008. PMID: 19669269 Free PMC article.
Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.
Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y. Ohkoshi S, et al. Among authors: yano m. Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70. Hepatogastroenterology. 2011. PMID: 21830425
2,778 results